Media Center

News Releases

Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA
July 27, 2015

NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA DUBLIN, IRELAND and WESTLAKE VILLAGE, CALIF. – July 27, 2015 – Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc….

KYTHERA Biopharmaceuticals Announces Health Canada Authorization of BELKYRA™, A Submental Contouring Injectable Drug
July 27, 2015

Recently Launched as KYBELLA™ in the U.S., BELKYRA™ deoxycholic acid Injection Improves Appearance and Profile of Moderate to Severe Submental Fullness or “Double Chin” Westlake Village, Calif., July 27, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it has received authorization from Health Canada to market BELKYRA™ “for improvement in the appearance of moderate…

KYTHERA Biopharmaceuticals Announces US Availability of KYBELLA™ – First FDA-Approved Injectable Treatment for “Double Chin” – Through KYBELLA™ Trained Physicians
June 19, 2015

Westlake Village, Calif., June 19, 2015 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced the U.S. availability of KYBELLA™ (deoxycholic acid) injection, the first and only FDA-approved non-surgical treatment for reduction of submental fullness, a common yet under-treated aesthetic condition also known as “double chin.” KYBELLA™ was approved in April by the U.S. Food and…

Allergan to Acquire KYTHERA Biopharmaceuticals
June 17, 2015

NEWS RELEASE CONTACTS: Allergan: Investors:Lisa DeFrancesco (862) 261-7152 Media:David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan to Acquire KYTHERA Biopharmaceuticals – Complements Allergan’s Existing Position in Facial Aesthetics – – Lead Product KYBELLATM the First and Only Approved Non-surgical Treatment for Reduction of Submental Fullness – – Enhances…

KYTHERA Biopharmaceuticals To Present at the Goldman Sachs 36th Annual Global Healthcare Conference
June 3, 2015

Westlake Village, Calif., June 3, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that John Smither, chief financial officer, will present at the Goldman Sachs 36th Annual Global Healthcare Conference. Event:      Goldman Sachs 36th Annual Global Healthcare Conference Date:       Tuesday, June 9, 2015 Time:       2:00 p.m. PT A live…

KYTHERA Biopharmaceuticals To Present at the Bank of America Merrill Lynch 2015 Health Care Conference
May 8, 2015

Westlake Village, Calif., May 8, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference. Event:      Bank of America Merrill Lynch 2015 Health Care Conference Date:       Thursday, May 14, 2015 Time:…

KYTHERA Biopharmaceuticals Releases First Quarter 2015 Operating Results and Progress Update
May 7, 2015

Company Well Positioned for Commercial Launch of KYBELLA™ (deoxycholic acid) Injection Westlake Village, Calif., May 7, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the first quarter of 2015, and provided an update on recent accomplishments. “KYTHERA recently achieved our most significant milestone to date, that of receiving FDA approval of KYBELLA™,…

KYTHERA Biopharmaceuticals To Release First Quarter 2015 Operating Results 
April 30, 2015

Westlake Village, Calif., April 30, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it will release its first quarter 2015 operating results and will host an investor call and webcast at 4:30 p.m. ET on Thursday, May 7, 2015. Individuals interested in participating in the call should dial (877) 344-3890 (U.S. and Canada) or…

KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) — First and Only Submental Contouring Injectable Drug
April 29, 2015

KYBELLA(TM) (deoxycholic acid) Injection Significantly Improves Submental Fullness, or “Double Chin” WESTLAKE VILLAGE, Calif., April 29, 2015 (GLOBE NEWSWIRE) — KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) announced today that the U.S. Food and Drug Administration (FDA) has approved KYBELLA™, also known as ATX-101, “for improvement in the appearance of moderate to severe convexity or fullness associated with submental…

KYTHERA Biopharmaceuticals Announces 2015 Outlook Call
March 19, 2015

Westlake Village, Calif., March 19, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it will host a 2015 Outlook investor call and webcast at 4:30 p.m. ET on Thursday, March 26, 2015. Individuals interested in participating in the call should dial (877) 344-3890 (U.S. and Canada) or (760) 666-3770 (international) using conference ID number…